Under the Pollution Prevention Act of 1990 (PPA), TRI collects information to track industry progress in reducing waste generation and moving towards safer waste management alternatives. Measures that facilities have taken to prevent pollution and reduce the amount of toxic chemicals entering the environment are shown in the table below. Although factors other than these reported practices contribute to year-to-year changes in releases, results are sorted by largest reduction in order to facilitate identification of pollution prevention successes. View the to learn about this report's features.

List of Facilities in TRI submitting Pollution Prevention Information for Selected Criteria:

Industry: Pharmaceutical Preparation Manufacturing Chemical: N,N-Dimethylformamide Year: between 2013 and 2021

P2 Text Filters: Only show information about source reduction activities Show information about source reduction AND other environmental practices Exclude facilities that reported activity codes but no text descriptions Show information on barriers to implementing source reduction activities Show ALL information reported in pollution prevention data fields Year-to-Year Comparison: Total Waste Total Release [displayed currently] Air Release Land Release Water Release

TRI Facility ID	Facility Name	Address	Chemical Name	Industry	Year	Prior Year Release *	Current Year Release *	Percent Change	Pollution Prevention Information (Activity Codes/Text/[Reduction])	P2 Report
9050WPLYPP365MA	POLYPEPTIDE LABORATORIES INC. (POLYPEPTIDE LABORATORIES INC)	365 MAPLE AVE, TORRANCE, CA 90503	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2013	433.00	5.00	-98.85	Source Reduction: W19: Other changes in operating practices - The company is utilizing lean manufacturing principles. Methods to Identify SR Opportunities: T04 : PARTICIPATIVE TEAM MANAGEMENT - Daily production scheduling meetings are held to address immediate concerns in addition to weekly project meetings which are held to plan longer term projects and actions.Methods to Identify SR Opportunities: T06 : EMPLOYEE RECOMMENDATION (UNDER A FORMAL COMPANY PROGRAM) - Continuous improvement is encouraged in all work procedures.
92126NMPSX9395C	POLYPEPTIDE LABORATORIES SAN DIEGO (POLYPEPTIDE LABORATORIES INC)	9395 CABOT DR, SAN DIEGO, CA 92126	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2015	9,582.00	116.00	-98.79	Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis
9050WPLYPP365MA	POLYPEPTIDE LABORATORIES INC. (POLYPEPTIDE LABORATORIES INC)	365 MAPLE AVE, TORRANCE, CA 90503	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2021	2,060.00	241.00	-88.3	Source Reduction: S21: Optimized process conditions to increase efficiency - PolyPeptide has an active ongoing program to optimize the utilization of Dimethylformamide. Source Reduction: PolyPeptide has an active ongoing program to optimize the utilization of Dimethylformamide.
92126NMPSX9395C	POLYPEPTIDE LABORATORIES SAN DIEGO (POLYPEPTIDE LABORATORIES INC)	9395 CABOT DR, SAN DIEGO, CA 92126	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2014	80,912.00	9,582.00	-88.16	Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis
92126NMPSX9395C	POLYPEPTIDE LABORATORIES SAN DIEGO (POLYPEPTIDE LABORATORIES INC)	9395 CABOT DR, SAN DIEGO, CA 92126	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2017	540.00	88.00	-83.7	Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis[-0-4%]
5302WCMBRDW132N	STERLING WISCONSIN LLC (GHO CAPITAL PARTNERS)	W132 N10550 GRANT DR, GERMANTOWN, WI 53022	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2013	617.00	213.00	-65.48	Source Reduction: W13: Improved maintenance scheduling, recordkeeping, or procedures - Thermal oxidizer is on a preventive manintenance schedule with better record keeping
08902RSQBBONESQ	E R SQUIBB & SONS LLC (BRISTOL-MYERS SQUIBB CO)	ONE SQUIBB DR, NORTH BRUNSWICK, NJ 08902	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2014	500.40	255.40	-48.96	Source Reduction: W13: Improved maintenance scheduling, recordkeeping, or procedures Other Environmental Practices: Waste Treatment - waste treated for energy recovery
9050WPLYPP365MA	POLYPEPTIDE LABORATORIES INC. (POLYPEPTIDE LABORATORIES INC)	365 MAPLE AVE, TORRANCE, CA 90503	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2020	3,058.00	2,060.00	-32.64	Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis
92126NMPSX9395C	POLYPEPTIDE LABORATORIES SAN DIEGO (POLYPEPTIDE LABORATORIES INC)	9395 CABOT DR, SAN DIEGO, CA 92126	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2019	239.00	163.00	-31.8	Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis - Dimethylformamide (DMF) is largest volume solvent that the PolyPeptide (PPL) Group currently employs in its manufacturing process. Through a combination of better washing efficiency, reuse and process analytics PPL aim to reduce DMF consumption by >25%.
92126NMPSX9395C	POLYPEPTIDE LABORATORIES SAN DIEGO (POLYPEPTIDE LABORATORIES INC)	9395 CABOT DR, SAN DIEGO, CA 92126	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2013	93,131.00	80,912.00	-13.12	Source Reduction: W15: Introduced an in-line product quality monitoring or other process analysis system Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis
95741RJTFNHWY5O	AMPAC FINE CHEMICALS LLC (FINE CHEMICALS HOLDING CORP)	HWY 50 & HAZEL RD, RANCHO CORDOVA, CA 95670	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2014	5.00	5.00	0	Source Reduction: W14: Changed production schedule to minimize equipment and feedstock changeovers Source Reduction: W21: Instituted procedures to ensure that materials do not stay in inventory beyond Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis
9050WPLYPP365MA	POLYPEPTIDE LABORATORIES INC. (POLYPEPTIDE LABORATORIES INC)	365 MAPLE AVE, TORRANCE, CA 90503	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2016	331.90	339.00	2.14	Source Reduction: W32: Improved procedures for loading, unloading, and transfer operations
92126NMPSX9395C	POLYPEPTIDE LABORATORIES SAN DIEGO (POLYPEPTIDE LABORATORIES INC)	9395 CABOT DR, SAN DIEGO, CA 92126	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2020	163.00	204.00	25.15	Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis
9050WPLYPP365MA	POLYPEPTIDE LABORATORIES INC. (POLYPEPTIDE LABORATORIES INC)	365 MAPLE AVE, TORRANCE, CA 90503	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2015	253.50	331.90	30.93	Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis[-0-4%] Methods to Identify SR Opportunities: T04 : PARTICIPATIVE TEAM MANAGEMENT - Our clients are changing their BOC chemistry to FMOC chemistry where possible at the outset of drug development which can reduce certain hazardous reactants with less hazardous reactants..
92126NMPSX9395C	POLYPEPTIDE LABORATORIES SAN DIEGO (POLYPEPTIDE LABORATORIES INC)	9395 CABOT DR, SAN DIEGO, CA 92126	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2021	204.00	282.00	38.24	Source Reduction: S21: Optimized process conditions to increase efficiency
47905LLLLYLILLY	EVONIK CORP TIPPECANOE LABORATORIES (EVONIK CORP)	1650 LILLY RD, LAFAYETTE, IN 47909	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2015	193.00	273.00	41.45	Source Reduction: W58: Other process modifications Other Environmental Practices: Methods for Identifying Pollution Prevention Opportunities - Almost all activities listed under Section 8 have been in place on this site for years. New and existing processes are constantly evaluated to identify and implement efficiency improvements that reduce waste. Production products, processes, and levels at this site are highly dynamic; processes using this compound are in constant flux.
47905LLLLYLILLY	EVONIK CORP TIPPECANOE LABORATORIES (EVONIK CORP)	1650 LILLY RD, LAFAYETTE, IN 47909	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2014	117.00	193.00	64.96	Other Environmental Practices: Ways P2 Was Incorporated in Original Process Design - Almost all activities listed under Section 8 have been in place on this site for years. New and existing processes are constantly evaluated to identify and implement efficiency improvements that reduce waste. Production products, processes, and levels at this site are highly dynamic; processes using this compound are in constant flux.
47905LLLLYLILLY	EVONIK CORP TIPPECANOE LABORATORIES (EVONIK CORP)	1650 LILLY RD, LAFAYETTE, IN 47909	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2016	273.00	515.00	88.64	Source Reduction: Ways P2 Was Incorporated in Original Process Design - Processes evaluated to identify potential environmental impacts and efficiency improvements; approaches implemented when high productions levels established, if applicable.
08902RSQBBONESQ	E R SQUIBB & SONS LLC (BRISTOL-MYERS SQUIBB CO)	ONE SQUIBB DR, NORTH BRUNSWICK, NJ 08902	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2013	255.00	500.40	96.24	Source Reduction: W19: Other changes in operating practices Other Environmental Practices: Material are used in fuels blending as appropriate.
47905LLLLYLILLY	EVONIK CORP TIPPECANOE LABORATORIES (EVONIK CORP)	1650 LILLY RD, LAFAYETTE, IN 47909	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2017	515.00	1,220.00	136.89	Other Environmental Practices: Energy Recovery - Waste containing DMF was sent for fuel blending in 2017.
47905LLLLYLILLY	EVONIK CORP TIPPECANOE LABORATORIES (EVONIK CORP)	1650 LILLY RD, LAFAYETTE, IN 47909	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2013	45.00	117.00	160	Other Environmental Practices: Almost all activities listed under Section 8 have been in place on this site for years. New and existing processes are constantly evaluated to identify and implement efficiency improvements that reduce waste. Production products, processes, and levels at this site are highly dynamic; processes using this compound are in constant flux.
92126NMPSX9395C	POLYPEPTIDE LABORATORIES SAN DIEGO (POLYPEPTIDE LABORATORIES INC)	9395 CABOT DR, SAN DIEGO, CA 92126	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2018	88.00	239.00	171.59	Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis[-0-4%]
92126NMPSX9395C	POLYPEPTIDE LABORATORIES SAN DIEGO (POLYPEPTIDE LABORATORIES INC)	9395 CABOT DR, SAN DIEGO, CA 92126	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2016	116.00	540.00	365.52	Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis
9050WPLYPP365MA	POLYPEPTIDE LABORATORIES INC. (POLYPEPTIDE LABORATORIES INC)	365 MAPLE AVE, TORRANCE, CA 90503	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2019	419.80	3,058.00	628.44	Source Reduction: W50: Optimized reaction conditions or otherwise increased efficiency of synthesis - Dimethylformamide (DMF) is largest volume solvent that the PolyPeptide (PPL) Group currently employs in its manufacturing process. Through a combination of better washing efficiency, reuse and process analytics PPL aims to reduce DMF consumption by >25%. Source Reduction: Dimethylformamide (DMF) is largest volume solvent that the PolyPeptide (PPL) Group currently employs in its manufacturing process. Through a combination of better washing efficiency, reuse and process analytics PPL aims to reduce DMF consumption by >25%.
9050WPLYPP365MA	POLYPEPTIDE LABORATORIES INC. (POLYPEPTIDE LABORATORIES INC)	365 MAPLE AVE, TORRANCE, CA 90503	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2014	5.00	253.50	4970	Source Reduction: W15: Introduced an in-line product quality monitoring or other process analysis system
9402WCSBCX2KELL	CSBIO (NA)	20 KELLY CT, MENLO PARK, CA 94025	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2020	272.01	120,343.80	44142.42	Source Reduction: W51: Instituted recirculation within a process - Implemented a "recycler" tank into the process, re-using spent solvent for an additional step in place of neat/new solvent. Methods to Identify SR Opportunities: T03 : MATERIALS BALANCE AUDITS - Material balance of the dispensed materials and process steps to calculate source reduction.
9402WCSBCX2KELL	CSBIO (NA)	20 KELLY CT, MENLO PARK, CA 94025	N,N-Dimethylformamide	325412: Pharmaceutical Preparation Manufacturing	2015	0	59,090.00		Source Reduction: W19: Other changes in operating practices[-0-4%]